Replies to post #145993 on Anavex Life Sciences Corp (AVXL)

[XenaLives]

Bingo!

The disparity of Market Caps between ACAD ($2.8 Bil. and as high as $5 Bil.) and AVXL ($122 Mil) is staggering, 23X. What would a similar valuation of Anaxex do to the price of AVXL stock? One does not have to have a great imagination to see what Anavex should be valued at today. Just examine the market caps of other CNS clinical stage companies like ACAD and Sage ($7 Bil with NO APPROVALS) or like AXON ($2.4 Bil, before) in its, Wall Street sponsored pre-clinical pump stage. Why is AVXL stock priced so low? That is the $63(thousand) question and may be partly due to Anavex not being a Wall Street Sponsored/Controlled company having not IPO'd with the controlling stock interests in the hands of Wall Street. Is Wall Street getting their shares by running over and running out retail holders as best they can with manipulation?

[Reyeton]

"The-Last-Company-Standing"

I-just-returned-from-Europe-and-watched-a-movie-on-the-plane.--It-is-called-

"Last-Flag-Flying"

It-had-me-laughing-out-loud-at-times-and-bowing-my-head-to-shield-the-tears-
that-filled-my-eyes-at-others.

Here-is-the-trailer:

[Phoenix64]

Has anyone given thought to Anavex should do a small share offering to get Wall Street on our side. It is clear we have big financial forces against avxl. Everyone acknowledges the stock is being held down because Missling won’t play ball. Maybe it is time for a change in this strategy. Just some thoughts.

[Amatuer17]

The question is valid and the answer/s are in plain sight -

1. Lack of progress - M is talking about A2-73 for so long without actually starting any new trial as promised

2. The trial size is very small with very inconclusive results - there is no confirmed MOA and confirm efficacy of whatever MOA co says

3. No BP or MP has shown confidence in the co by entering into any kind of collaboration

4. With reasons above - market does not believe anything M says - there is lack of credibility.

The lack of credibility, lack of high cash, lack of strong trial results and missing promised new trials - all are reflected in the current market cap

Do better execution, start new trial and start some believable strong results and SP will move in right direction.